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The maintenance of homeostasis between the gut microbiota and human host tissues entails a complex co-evolutionary relationship1,2. Mucosal barriers covering the intestinal epi-
thelium restrict microbes to the lumen, control the composition 
of commensal inhabitants and ensure the removal of pathogens3,4. 
Cationic host antimicrobial peptides (AMPs) have crucial roles in 
this process5. They are among the most ancient and efficient com-
ponents of the innate immune defence in multicellular organisms 
and have retained their efficacy for millions of years5,6. As AMPs 
have a broad spectrum of activity, much effort has been put into 
finding potential antibacterial drugs among AMPs7,8.
However, therapeutic use of AMPs may drive bacterial evolu-
tion of resistance to our own immunity peptides9,10. Therefore, it 
is of central importance to establish whether genes that influence 
AMP resistance (AMP resistance genes) in the gut microbiome 
are available for genetic exchange with other bacterial species. 
Several lines of observation support the plausibility of this sce-
nario. The gut bacterial community is a rich source of mobile 
antibiotic resistance genes11, and certain abundant gut bacte-
rial species exhibit high levels of intrinsic resistance to AMPs12. 
Moreover, even single genes can confer high AMP resistance 
in Bacteroidetes12. However, beyond the recent discovery of a 
horizontally spreading resistance gene family13,14, the mobility 
of AMP-resistance-encoding genes across bacterial species has 
remained unknown.
Here, we have applied an integrated approach to systematically 
characterize the mobilization potential of the AMP resistance gene 
reservoir in the human gut microbiome. First, we examined the pat-
terns of horizontal gene transfer events involving AMP resistance 
genes by analysing bacterial genome sequences from the human 
gut and naturally occurring plasmid sequences from the human 
microbiome. Next, we experimentally compared the functional 
compatibility of AMP resistance versus antibiotic resistance genes 
from the gut microbiome with a susceptible host, Escherichia coli, by 
performing functional metagenomic selections and by culturing the 
gut microbiome in the presence of diverse AMPs and small-mole-
cule antibiotics. Together, these analyses revealed that AMP resis-
tance genes are less frequently mobilized owing to lack of functional 
compatibility with new bacterial hosts.
Results
Infrequent horizontal transfer of AMP resistance genes in the gut 
microbiota. We begin by asking whether the genetic determinants 
of resistance to AMPs and antibiotics, respectively, differ in their 
rate of horizontal transfer in the human gut microbiota. To system-
atically address this issue, we first collected previously character-
ized AMP and antibiotic resistance genes from the literature and 
databases, yielding a comprehensive catalogue of 114 and 199 AMP 
resistance and antibiotic resistance gene families, respectively (see 
Methods and Supplementary Table 1). By definition, AMP resistance 
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genes influence bacterial susceptibility to at least one AMP when 
mutated (see Methods). Next, we compared the frequencies of 
these previously identified AMP and antibiotic resistance genes 
in a catalogue of 37,853 horizontally transferred genes from 567 
genome sequences of phylogenetically diverse bacterial species in 
the human gut microbiota15. This mobile gene catalogue relies on 
the identification of nearly identical genes that are shared by dis-
tantly related bacterial genomes and thereby provides a snapshot of 
the gene set subjected to recent horizontal gene transfer events in a 
representative sample of the human gut microbiome15. We identi-
fied homologues of the literature-curated resistance genes for which 
at least one transfer event was reported (that is, those present in the 
mobile gene pool; see Methods and Supplementary Table 2).
We found that the relative frequency of AMP resistance genes 
within the pool of mobile genes was 4.8-fold lower than that of 
antibiotic- resistance genes, in spite of their similar frequencies in 
the genomes of the gut microbiota (Fig. 1a, Supplementary Fig. 1a  
and Supplementary Table 2). Notably, the relative under-represen-
tation of AMP resistance genes in the mobile gene pool cannot be 
simply attributed to the large physiological differences between 
Gram-negative and Gram-positive bacteria. When these two bac-
terial groups were considered individually, AMP resistance genes 
remained under-represented in the mobile gene pool compared to 
antibiotic resistance genes (Fig. 1a). Moreover, the unique trans-
ferred AMP resistance genes were shared between fewer bacterial 
species, indicating fewer transfer events per gene (Fig. 1b). Notably, 
65% of these transfer events mobilized AMP-transporting efflux 
pumps between bacteria within the Firmicutes phylum (Fig. 1c, 
Supplementary Fig. 1b and Supplementary Table 3).
To further support the low mobility of AMP resistance genes, 
we next explored whether AMP resistance genes from our litera-
ture-curated list are associated with naturally occurring plasmid 
sequences or integrative conjugative elements (ICEs) in the human 
gut microbiome (see Methods). Strikingly, while 86% of the antibi-
otic resistance genes had close homologues on plasmids, only 33% of 
the AMP resistance genes did (Fig. 1d and Supplementary Table 4). 
Moreover, the plasmids carrying individual antibiotic resistance 
genes were more widespread across bacterial species than those 
carrying AMP resistance genes (Fig. 1e). Notably, many of these 
plasmid-encoded AMP resistance genes were proteases and efflux 
pumps carried by virulence or multi-drug resistance plasmids in 
the human microbiome (Supplementary Table 4). Finally, as with 
plasmid sequences, we found that disproportionately fewer AMP 
resistance genes had homologues in ICEs than antibiotic resistance 
genes (Supplementary Fig. 2 and Supplementary Table 4).
Overall, these results suggest that AMP resistance genes are 
less frequently transferred across bacterial species in the human 
microbiota.
Short genomic fragments from the gut microbiota rarely confer 
AMP resistance. One possible reason for the low mobilization of 
AMP resistance genes could be that AMP resistance is an intrinsic 
property of certain bacteria shaped by multi-gene networks10. Genes 
involved in AMP resistance may display strong epistatic interac-
tions, and therefore they may have little or no impact on resistance 
individually. If this was so, horizontal gene transfer of single genes 
or transcriptional units encoded by short genomic fragments would 
not provide resistance in the recipient bacterial species. Indeed, 
AMPs interact with the cell membrane, a highly interconnected cel-
lular structure, and membership in complex cellular subsystems has 
been shown to limit horizontal gene transfer16,17.
To investigate this scenario, we experimentally compared the 
ability of short genomic fragments to transfer resistance pheno-
types towards AMPs versus antibiotics. To this end, we applied an 
established functional metagenomic protocol11,18 to identify ran-
dom 1.5–5 kb DNA fragments in the gut microbiome that confer 
resistance in an intrinsically susceptible E. coli strain. Importantly, 
the length distributions of the known AMP resistance and anti-
biotic resistance genes are well within this fragment size range 
(Supplementary Fig. 3), indicating that our protocol is suitable 
to capture single resistance genes for both AMPs and antibiotics. 
Metagenomic DNA from human gut faecal samples was isolated 
from two unrelated, healthy individuals who had not taken any 
antibiotics for at least one year. The resulting DNA samples were 
cut, and fragments between 1.5 and 5 kb were shotgun cloned into 
a plasmid to express the genetic information in E. coli K-12. About 
2 million members from each library, corresponding to a total 
coverage of 8 Gb (the size of ~2,000 bacterial genomes), were then 
selected on solid culture medium in the presence of one of 12 diverse 
AMPs and 11 antibiotics (Supplementary Table 5) at concentrations 
where the wild-type host strain is susceptible. Finally, using a third-
generation long-read sequencing pipeline19, the number of unique 
DNA fragments conferring resistance (that is, resistance contigs) 
was determined.
In agreement with earlier studies11,20, multiple resistant clones 
emerged against all tested antibiotics (Fig. 2a and Supplementary 
Table 6). In sharp contrast, no resistance was conferred against half 
of the AMPs tested, and, in general, the number of unique AMP 
resistance contigs (N = 34) was substantially lower than the num-
ber of unique antibiotic resistance contigs (N = 119) (Fig. 2a and 
Supplementary Table 6). Polymyxin B—an antimicrobial peptide 
used as a last-resort drug in the treatment of multidrug-resistant 
Gram-negative bacterial infections21—is a notable exception to this 
trend, with a relatively high number of unique resistance contigs 
(Fig. 2a). Indeed, a resistance gene (mcr-1) against polymyxin B is 
rapidly spreading horizontally worldwide, representing an alarming 
global healthcare issue22. In contrast to polymyxin B, we detected 
only one unique contig conferring resistance to LL37, a human AMP 
abundantly secreted in the intestinal epithelium23 (Supplementary 
Table 6). These specific AMP resistance genes are involved in cell 
surface modification, peptide proteolysis and regulation of the outer 
membrane stress response (Table 1, Supplementary Table 6 and 
Supplementary Fig. 4).
If lack of functional compatibility with the host cell prevents 
AMP resistance genes from exerting their phenotypic effects, 
then DNA fragments identified in our screen should more often 
come from phylogenetically closely related bacteria. A total of 
53% of the contigs showed over 95% sequence identity to bacte-
rial genome sequences from the HMP database24 (see Methods 
and Supplementary Fig. 5), allowing us to infer the source taxa 
with high accuracy (Supplementary Table 6). Indeed, while antibi-
otic resistance contigs were over-represented from Firmicutes, the 
most abundant phylum in the gut, AMP resistance contigs origi-
nated excessively from Proteobacteria, which are phylogenetically 
close relatives of the host E. coli (Fig. 2b and Supplementary Fig. 6). 
Notably, this trend was not driven by polymyxin B only, but was 
valid for the rest of the AMPs as well (Supplementary Fig. 6).
Whereas these patterns are consistent with the hypothesis that 
the genetic determinants of AMP resistance are difficult to transfer 
via short genomic fragments owing to a lack of functional compat-
ibility with the new host, another explanation is also plausible. In 
particular, AMP-resistant bacteria might be relatively rare in the 
human gut microbiota, so AMP resistance genes from these bacteria 
might simply remain undetected. However, as explained below, we 
can rule out this alternative hypothesis.
AMP resistant gut bacteria are abundant and phylogenetically 
diverse. To assess the diversity and taxonomic composition of gut 
bacteria displaying resistance to AMPs and antibiotics, we carried 
out anaerobic cultivations and selections of gut microbiota using 
a state-of-the-art protocol25. To this end, faecal samples were col-
lected from seven healthy individuals (Faecal 7 mix, see Methods). 
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As expected25, the cultivation protocol allowed representative sam-
pling of the gut microbiota: we could cultivate 65–74% of the gut 
microbial community at the family level in the absence of any drug 
treatment (Supplementary Fig. 7 and Supplementary Table 7). Next, 
the same faecal samples were cultivated in the presence of one of 
5–5 representative AMPs and antibiotics (Supplementary Table 8). 
We applied drug dosages that retained 0.01–0.1% of the total cell 
populations from untreated cultivations (Supplementary Table 8) 
and assessed the taxonomic composition of these cultures by 16S 
rRNA sequencing (see Methods).
Remarkably, the diversities of the AMP-treated and untreated 
bacterial cultures did not differ significantly from each other 
(Fig. 3a), despite marked differences in their taxonomic composi-
tions (Fig. 3b). AMP-treated samples contained several bacterial 
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Fig. 1 | AMP resistance genes are less frequently transferred in the human gut microbiome than antibiotic resistance genes. a, Percentage of AMP 
resistance genes (AMP, red bars) and antibiotic resistance genes (AB, blue bars) detected as horizontally transferred (that is, present in the mobile 
gene pool). Resistance genes were identified using BLAST sequence similarity searches in the genome sequences of the gut microbiota (see Methods). 
***Significant difference (left to right): P =  2 ×  10−16, 4 ×  10−16, 2 ×  10−13 from two-sided binomial test, in each case n =  100 both for AMPs and ABs). 
Centre and error bars represent mean and s.d. values calculated by randomly sampling 100 times from each of the 225 operational taxonomic units 
(OTUs), respectively (see Methods and Supplementary Table 2). b, Unique mobile AMP resistance genes were involved in half as many between-species 
transfer events as antibiotic resistance genes (P =  0.01, two-sided negative binomial regression, n =  19 and 50 for AMP and antibiotic resistance genes, 
respectively). The result remains when a non-parametric test is used, which is less sensitive to outliers (P =  0.02, two-sided Mann–Whitney U test). OTUs 
were generated as for a (Supplementary Table 3). On the x axes, the continuity of the scale breaks between 10 and 12. Above 12, only values with at least 
one transferred resistance gene are shown. c, Network representation of the mobile gene pool in the case of AMP and antibiotic resistance genes. Straight 
and curved lines represent genes that were shared between OTUs of different phyla and the same phylum, respectively. Line thickness represents the 
number of resistance genes shared between OTUs of six major phyla. Node size and numbers in parentheses indicate the number of OTUs in each phylum 
that shared at least one transferred AMP or antibiotic resistance gene. OTUs were generated as for a. d, Significantly fewer AMP resistance genes (46 
out of 137) have a close homologue in naturally occurring plasmid sequences in the human microbiome as compared to antibiotic resistance genes (1,867 
out of 2,163) (P =  2.2 ×  10−6, two-sided Fisher’s exact test). n =  137 and 2,163 for AMPs and ABs, respectively (see Methods and Supplementary Table 4). 
e, Plasmid-encoded homologues of individual AMP resistance genes were found in significantly fewer species in the human microbiome as compared to 
antibiotic resistance genes (P =  5.6 ×  10−15, two-sided negative binomial regression, n =  23 for AMPs and n =  1,772 for antibiotics, see Methods).
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families from the Firmicutes and Actinobacteria phyla, which are 
phylogenetically distant from E. coli (Fig. 3c). Notably, exposure 
to AMP stress provided a competitive growth advantage to bacte-
rial families that remained undetected in the untreated samples 
(Fig. 3c). The examples include Desulfovibrionaceae, Clostridiaceae 
and Eubacteriaceae. Desulfovibrionaceae is a clinically relevant 
bacterial family that is linked to ulcerative colitis26—an inflamma-
tory condition with elevated AMP levels27, while Clostridiaceae 
and Eubacteriaceae have key roles in maintaining gut homeosta-
sis28 (Fig. 3c). In sharp contrast, the diversity of antibiotic-treated 
cultures dropped significantly compared to both the untreated and 
AMP-treated cultures (Fig. 3a and Supplementary Fig. 8). Several 
bacterial families had a significantly lower abundance in the anti-
biotic-treated cultures than in the untreated ones (Fig. 3c). These 
results indicate that the human gut is inhabited by a large number 
of bacterial families across all major phyla in the gut that exhibit 
intrinsic resistance to AMPs.
Human microbiota harbours a large reservoir of AMP resis-
tance genes. Next, we assessed if the high taxonomic diversity 
in the AMP-resistant microbiota corresponds to a diverse reser-
voir of AMP resistance genes. To this end, we annotated previ-
ously identified AMP- and antibiotic-resistance genes in a set of 
gut bacterial genomes16 representing bacterial families that were 
detected in our culturing experiments following AMP and anti-
biotic selection, respectively (Fig. 3c; for details, see Methods). 
Remarkably, 65% of our literature-curated AMP resistance gene 
families (Supplementary Table 1) were represented in at least one 
of these genomes (Supplementary Table 2), which is similar to the 
value for antibiotic resistance gene families (58%). Finally, AMP 
resistance gene families, on average, were 39% more widespread 
in these species than the same figure for antibiotic resistance 
genes (Supplementary Fig. 9). Thus, the human gut harbours 
diverse AMP-resistant bacteria and a large reservoir of AMP 
resistance genes.
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Fig. 2 | In E. coli, short genomic fragments from the human gut microbiota confer AMP resistance less frequently than antibiotic resistance. a, Functional 
selection of metagenomic libraries with 12 AMPs (red bars) resulted in fewer distinct resistance-conferring DNA contigs than with 11 conventional small-
molecule antibiotics (ABs, blue bars). P =  0.002 from two-sided negative binomial regression, n =  34 AMP resistance contigs, n =  119 antibiotic resistance 
contigs. Red asterisks indicate zero values. **Significant difference between AMPs and antibiotics. b, Phylum-level distribution (%) of the AMP resistance 
(red bars) and antibiotic resistance contigs (blue bars). In the case of AMPs, significantly more resistance contigs originate from the Proteobacteria 
phylum (P =  0.015, two-tailed Fisher’s exact test, n =  110), while contigs originating from the Firmicutes phylum are under-represented (P =  0.033, two-
tailed Fisher’s exact test, n =  110). *Significant difference between AMPs and antibiotics for a given phylum.
Table 1 | List of putative AMP resistance genes identified from our functional metagenomic screens
Resistance gene Resistance gene function Classification of 
resistance function
Estimated source organism uniProt IDd AMP
lpxFa Lipid A 4′ -phosphatase Target alteration Parabacteroides merdae A7AEQ0 Polymyxin B, 
pexiganan
lpxFb Lipid A 4′ -phosphatase Parabacteroides sp. A0A355WPL4 Polymyxin B, 
pexiganan
lpxFc Lipid A 4′ -phosphatase NA A0A0F5J1Y0 Polymyxin B
arnTEF 4-amino-4-deoxy-l-
arabinose modification of 
lipid A
E. coli MS 107-1 P76473  
Q47377  
P76474
Polymyxin B
pmrAB (qseBC) Response regulator Regulation Sutterella wadsworthensis 
2_1_59BFAA
A0A139KIR1 
A0A139KIX7
Polymyxin B
pmrD Signal transduction protein E. coli MS 107-1 P37590 Polymyxin B
ompT Protease 7 precursor Agent inactivation E. coli MS 196-1 P09169 Bactenecin 5, LL37, 
pexiganan
These resistance genes could be functionally annotated based on a literature-curated catalogue of resistance genes (Supplementary Table 1). NA (not available) indicates that the donor organism 
could not be identified based on the Human Microbiome Project Database (see Methods). aCharacterized in this work (Fig. 4b,c and Supplementary Fig. 11); annotated as undecaprenyl pyrophosphate 
phosphatase in Supplementary Table 6. bAnnotated as bcrC in Supplementary Table 6. cAnnotated as ybjG in Supplementary Table 10. dClosest homologues of the metagenomic hits in UniProt database.
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Phylogenetic constraints on the functional compatibility of AMP 
resistance genes. We next directly tested whether the shortage of 
AMP resistance DNA fragments from distantly related bacteria can be 
explained by the low potential of genomic fragments to transfer AMP 
resistance phenotypes to E. coli. To this end, we constructed metage-
nomic libraries from the AMP- and antibiotic-resistant microbiota 
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resistant microbiota, respectively, and 33 and 54 for the number of transferred AMP-resistant and AB-resistant contigs, respectively.
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cultures. From each AMP and antibiotic treatment, two biological 
replicates were generated (see Methods), resulting in 10–10 librar-
ies, covering 25.6 Gb and 14 Gb DNA, respectively (Supplementary 
Table 9). These metagenomic libraries were next screened on the cor-
responding AMP- or antibiotic-containing solid medium. Finally, the 
phylogenetic sources of the resulting AMP resistance and antibiotic 
resistance contigs were inferred with high confidence (Supplementary 
Fig. 10 and Supplementary Table 10). Compared to their relative 
frequencies in the drug-treated cultured microbiota, the phyloge-
netically close Proteobacteria contributed disproportionately more 
AMP resistance than antibiotic resistance DNA fragments, whereas 
the opposite pattern was seen for the distantly related Firmicutes 
(Fig. 3d and Supplementary Table 11). Taken together, phylogeneti-
cally diverse gut bacterial species show AMP resistance, but there is a 
shortage of transferable AMP resistance DNA fragments from phylo-
genetically distant relatives of E. coli.
Pervasive genetic background dependence of AMP resistance 
genes. Finally, we present evidence that DNA fragments that confer 
resistance to AMPs and were isolated from our screens show stron-
ger genetic background dependence than those conferring resis-
tance to antibiotics.
To systematically test the genetic background-dependency of 
AMP resistance genes, we examined how DNA fragments that pro-
vide AMP or antibiotic resistance in E. coli influence drug suscep-
tibility in a related Enterobacter species, Salmonella enterica. We 
analysed a representative set of 41 resistance-conferring DNA frag-
ments derived from our screens (Supplementary Table 12) by mea-
suring the levels of resistance provided by them in both E. coli and 
S. enterica. Strikingly, while 88% of the antibiotic resistance DNA 
fragments provided resistance in both host species, only 38.9% of 
AMP resistance DNA fragments did so (Fig. 4a and Supplementary 
Table 12). Thus, the phenotypic effect of AMP resistance genes 
frequently depends on the genetic background, even when closely 
related hosts are compared.
As an example, we finally focused on a putative orthologue of a 
previously characterized AMP resistance gene, lpxF (ref. 12). LpxF is 
a key determinant of AMP resistance in Bacteroidetes, a member of 
the human gut microbiota. By decreasing the net negative surface 
charge of the bacterial cell, it provides a 5,000-fold increment in 
polymyxin B resistance in these species13,29. To test the impact of one 
of the lpxF orthologues identified in our screen (denoted lpxFa in 
Table 1) on AMP resistance in a new bacterial species, we expressed 
it in wild-type and a mutant E. coli strain (Δ lpxM) as well. Similarly 
to Bacteroidetes, the Δ lpxM strain uniquely synthesizes penta-acyl-
ated lipid A molecules, the natural substrate of lpxF, and is therefore 
especially suitable for testing the impact of the isolated lpxF ortho-
logue30. Reassuringly, surface charge measurements confirmed that 
the lpxFa is fully functional in E. coli (Fig. 4b and Supplementary 
Fig. 11). However, it provided a mere fivefold increase in polymyxin 
B resistance in E. coli, even in the Δ lpxM background (Fig. 4c). 
Notably, unlike the previously characterized lpxF from F. novicida30, 
the lpxF orthologue isolated from our screen was active both on the 
penta- and hexa-acylated lipid A molecules (Fig. 4b,c). Therefore, 
substrate specificity alone is unlikely to limit transfer of lpxFa into 
E. coli or other Enterobacteriaceae species. The compromised resis-
tance phenotype conferred by lpxFa in the new host shows that the 
function of other genes is also required to achieve the high AMP 
resistance level seen in the donor bacterium.
Discussion
This work systematically investigated the mobility of AMP resis-
tance versus antibiotic resistance genes in the gut microbiome. We 
report that AMP resistance genes are less frequently transferred 
between members of the gut microbiota than antibiotic resistance 
genes (Fig. 1). In principle, this pattern could be explained by at 
least two independent factors: shortage of relevant selection regimes 
during the recent evolutionary history of the gut microbiota and 
lack of functional compatibility of AMP resistance genes on transfer 
to a new host. We focused on testing the second possibility due to 
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Fig. 4 | AMP resistance DNA fragments provide host-dependent phenotypic effects. a, A significantly lower proportion of AMP resistance DNA 
fragments (AMPs, red bars) conferred resistance in both E. coli and S. enterica compared to antibiotic resistance DNA fragments (ABs, blue bars), 
suggesting weaker between-species conservation of the AMP resistance phenotypes. Asterisks indicate significant difference, P =  0.0011, two-sided 
Fisher’s exact test, n =  16 for AMPs, n =  25 for ABs. b, The lpxF orthologue from P. merdae, isolated in our screen (marked as lpxFa here and in Table 1; 
represented in green) and a previously characterized fully functional lpxF from Francisella novicida61 (marked as lpxF*) decrease the net negative surface 
charge of ∆ lpxM E. coli to a similar extent, and close to the level of wild-type Bacteroides thetaiotaomicron (BT) expressing its native lpxF. LpxFa has a 
similar effect both in ∆ lpxM and wild-type E. coli (dark and light green dots). The fluorescence signal is proportional to the binding of the fluorescein 
isothiocyanate (FITC)-labelled poly-l-lysine polycationic molecules. Less poly-l-lysine binding reflects a less negative net cell surface charge62. Significant 
differences: *P =  0.03, **P =  0.001 and ***P =  0.0004, respectively, Welch’s two-sample t-test, n =  4 biological replicates; central horizontal bars represent 
mean values. Corresponding microscopic pictures are shown in Supplementary Fig. 11. c, LpxFa increases polymyxin B resistance of both ∆ lpxM and wild-
type E. coli only fivefold (dark and light green bars) (n =  3), to the same extent as LpxF from F. novicida (marked as lpxF*) (n =  3). In contrast, lpxF in its 
original host, B. thetaiotaomicron (marked as lpxF**) provides a 5,000-fold increment in polymyxin B resistance13.
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its experimental tractability and relevance to forecast the mobility 
of resistance genes upon AMP treatment. In a series of experiments, 
we showed that phylogenetically diverse gut bacteria display high 
levels of AMP resistance (Fig. 3), yet the underlying resistance genes 
individually often fail to confer resistance upon transfer to E. coli 
(Figs. 2 and 3). Furthermore, we demonstrated that the AMP resis-
tance conferred by 1.5–5 kb genomic fragments often depends on 
the genetic background of the recipient bacterium (Fig. 4). Together, 
these results support the notion that horizontal acquisition of AMP 
resistance is constrained by phylogenetic barriers owing to func-
tional incompatibility with the new host cell31.
An important issue is whether the simultaneous transfer of 
multiple AMP resistance genes carried by longer DNA segments 
is feasible and can provide resistance to recipient bacteria. While 
this is certainly a realistic possibility, bioinformatic analyses sup-
port the conclusions derived from the metagenomic screens: AMP 
resistance genes are relatively rare in the mobile gene pool and on 
plasmids in nature (Fig. 1).
We speculate that the large differences in functional compatibil-
ity between antibiotic resistance and AMP resistance genes might 
be caused by the latter being more often part of highly intercon-
nected cellular subsystems, such as cell envelope biosynthesis path-
ways. We note that the compromised benefit may not be the only 
manifestation of functional incompatibility and the exclusive rea-
son for the limited presence of AMP resistance genes in the mobile 
gene pool and on plasmids (Fig. 1). It is also plausible that some 
AMP resistance genes have severe deleterious side effects in the 
new host in addition to conferring a compromised resistance. For 
example, the introduction of lpxF into bacterial pathogens reduces 
virulence in mice, probably because it perturbs the stability of the 
bacterial outer membrane in enterobacterial species32. Future works 
should elucidate whether AMP resistance genes are especially prone 
to induce deleterious side effects compared to antibiotic resistance 
ones. Clearly, deciphering the biochemical underpinnings of func-
tional incompatibility of AMP resistance genes remains an area for 
future research.
Our results also provide mechanistic insights into the functional 
capacity of AMPs to control the composition and stability of the 
gut microbiome over evolutionary timescales. Specifically, as phy-
logenetic barriers limit the horizontal transfer of AMP resistance 
mechanisms, the exact dosages and combinations of AMPs could 
prove to be critical for the long-term advantage of gut bacterial spe-
cies involved in human health. Indeed, our work indicates that spe-
cific AMP stresses can lead to an increase in the amount of bacteria 
linked to ulcerative colitis (Desulfovibrionaceae).
Another important and unresolved issue is why natural AMPs 
that are part of the human innate immune system have remained 
effective for millions of years without detectable resistance in sev-
eral bacterial species. One possibility, supported by our work, is that 
the acquisition of resistance through horizontal gene transfer from 
human gut bacteria is limited, most probably due to compromised 
functional compatibility in the recipient bacteria. We do not wish 
to claim, however, that AMPs in clinical use would generally be 
resistance-free. In agreement with the prevalence of polymyxin B 
resistance DNA fragments (Fig. 2a), a plasmid conferring colistin 
resistance is spreading globally33. Rather, our work highlights major 
differences in the frequencies and mechanisms of resistance across 
AMPs, with the ultimate aim to identify antimicrobial agents less 
prone to resistance.
Methods
Establishing a comprehensive AMP resistance gene data set. Even though several 
databases have been created for antibiotic resistance genes, a comprehensive list 
of AMP resistance genes has not been compiled so far. We therefore carried out 
a systematic literature mining in PubMed NCBI and Google Scholar with the 
keywords ‘antimicrobial peptide’ + ‘resistance’. From the identified publications, 
genes with experimentally confirmed influence on AMP susceptibility were 
included in our manually curated AMP resistance gene data set (Supplementary 
Table 1). Altogether, 138 AMP resistance genes were identified. As a next step, 
the compiled AMP resistance genes were classified into resistance gene families 
(orthologous gene groups or orthogroups) using EggNOG-mapper software 
(version 0.12.7) on the bacterial EggNOG 4.5.1 database34. Then, AMP resistance 
genes were classified into broad functional categories analogous to the classification 
of antibiotic resistance genes in The Comprehensive Antibiotic Resistance Database 
(CARD)35. To obtain a comparable data set for known antibiotic resistance genes 
we downloaded the CARD database35. Genes associated AMP resistance in CARD 
were filtered out and the remaining antibiotic resistance genes from CARD were 
grouped into resistance gene families in the same way as AMP resistance genes 
using the EggNOG database (Supplementary Table 1).
Analysis of the mobile gene pool of the gut microbiota. A previously published 
mobile gene catalogue of the human gut microbiota15 was analysed to compare 
the patterns of horizontal gene transfer events involving AMP and antibiotic 
resistance genes across a wide range of bacteria. This mobile gene catalogue relies 
on the identification of nearly identical genes in distantly related bacterial genomes 
and thereby provides a snapshot of the gene set subjected to recent horizontal 
gene transfer events in a representative sample of the gut microbiota. The goal 
in our analysis was to determine the presence/absence pattern of the AMP and 
antibiotic resistance genes not only in the mobile gene pool but also in the 567 
genomes from which the mobile gene pool was derived. In this way, not only the 
horizontally transferred resistance genes were identified but also those that have 
not been detected in such transfer events, but were present in the gut microbiome. 
To this end, the genomes and proteomes used by Brito and colleagues15 were 
downloaded from the Human Microbiome Project (HMP) database (https://www.
hmpdacc.org/HMRGD/) and from the Fijicomp website (http://www.fijicomp.
org). DNA sequences derived from the latter database were used for open reading 
frame (ORF) prediction with Prodigal software (version 2.6.336). Then, a sequence 
similarity search was applied to the compiled list of proteins encoded in the 
analysed genomes to identify those that were present in the mobile gene pool as 
well. The sequence similarity search between the mobile gene pool and the proteins 
from the genomes was carried out with the BLASTX option of Diamond software 
(version 0.9.1037) with 50% sequence coverage and 100% sequence identity 
(parameters were chosen to reproduce the original publication of the mobile gene 
pool15). Of the 37,870 unique mobile genes in the mobile gene pool, we identified 
37,184 in the genomes (98.28%).
Next, both the antibiotic and AMP resistance genes were identified among 
the mobile genes and among those that have not been detected in the mobile gene 
pool but were present in the genomes. For this functional annotation, a BLAST 
search was carried out against the antibiotic resistance genes from the CARD 
database with the BLASTP option of the Diamond software with strict parameters 
(e-value < 10−5, > 40% identity at the protein level and 80% query sequence 
coverage) (Supplementary Table 2). In a similar vein, AMP resistance genes 
were identified by performing a BLASTP sequence similarity search against the 
manually curated list of AMP resistance genes (Supplementary Table 1). Antibiotic 
and AMP resistance genes in our databases were classified into resistance gene 
families by the EggNOG-mapper software on the bacterial EggNOG database 
(Supplementary Table 2). For the annotated resistance gene list in the mobile gene 
pool, see Supplementary Table 3.
To compare the relative frequency of the AMP and antibiotic resistance 
genes in the mobile gene pool (Fig. 1a), we restricted the analysis to one genome 
per species. This was necessary to avoid sampling bias because different species 
were represented by unequal numbers of genomes in the data set. To this end, 
16S rRNA sequences were determined for each genome (for HMP genomes they 
were downloaded from the Silva database38, and for Fijicomp genomes they were 
identified directly in the genomes using RNAmmer software (version 1.239). Then, 
genomes with fewer than 2% 16S rRNA gene dissimilarities were collapsed into 
genome groups (‘species’ or OTUs) using average linkage clustering as described in 
the publication of the mobile gene pool15. Each such genome group was represented 
by one randomly chosen genome for the statistical analysis presented in Fig. 1a 
(note that the random sampling was repeated 100 times, yielding an estimate of 
standard error). Resistance genes in the mobile gene pool that resulted in a BLAST 
hit both from the AMP and the antibiotic resistance databases were excluded 
from the analysis. The remaining resistance genes annotated in the mobile gene 
pool were counted and plotted as the percentage of the total number of annotated 
resistance genes in the genome sequences (‘All bacteria’ from Fig. 1a). Additionally, 
the analysis was separately performed for the Gram-negative and Gram-positive 
bacterial genomes as well (‘Gram-positive’ and ‘Gram-negative’ in Fig. 1a). For the 
network representation of the mobile gene pool, we used Cytoscape40.
For each unique mobile AMP or antibiotic resistance gene we also estimated 
the minimum number of independent transfer events (Fig. 1b) by counting the 
number of genome groups (that is, OTUs) in which the gene is present in the 
mobile gene pool16 (Supplementary Table 3).
Identification of homologues of the literature-curated AMP resistance and 
antibiotic resistance genes in naturally occurring plasmid sequences and 
in ICEs. For the identification of plasmid-encoded AMP resistance genes, we 
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used two independent databases: a plasmid-encoded protein database from the 
NCBI Reference Sequence Database (Refseq)41 (ftp://ftp.ncbi.nih.gov/refseq/
release/plasmid/) and a curated plasmid database containing 2,097 entire 
plasmid sequences from the Enterobacteriaceae bacteria42 (https://figshare.
com/s/18de8bdcbba47dbaba41). From the Refseq database, protein sequences were 
downloaded and both the antibiotic and AMP resistance proteins were identified 
with the BLASTP algorithm using our literature-curated lists of resistance genes. 
Hits were accepted only if they showed > 40% sequence similarity over 80% of the 
length of the subject protein, with an e-value less than 10−5. Because this Refseq 
data set contains plasmid-encoded proteins from various sources in addition to 
the human microbiota, we filtered our hits using a previously compiled list of 
species from the human microbiota43. Thus, only those resistance gene hits were 
retained that are present on plasmids from human-associated bacteria. From 
the Enterobacteriaceae-specific plasmid database, we downloaded the translated 
nucleotide sequences for all six reading frames and carried out the similarity search 
as above using BLASTP with 80% query coverage, and > 40% sequence identity. For 
this data set, we manually checked the presence of the plasmid-encoded resistance 
genes in the human microbiome using the NCBI database (Supplementary Table 
4). Finally, we took the union of these two data sets to calculate the percentage of 
resistance genes residing on plasmids (Fig. 1d).
To estimate the species-level distribution of the plasmid-encoded resistance 
proteins we used the Refseq data set only as it gives information on the identity 
of species from which the plasmids were isolated. Specifically, for each AMP 
and antibiotic resistance gene that resulted in plasmid-encoded homologues, we 
counted the number of species that bore at least one plasmid-encoded homologue 
of the given AMP and antibiotic resistance gene (Fig. 1e).
For the identification of AMP resistance genes that are associated with ICEs, 
we used a database that contains 16,820 cargo genes associated with ICE sequences 
from human gut bacterial genome sequences (Intestinal Microbiome Mobile 
Element Database, https://immedb.org/)44. Nucleotide sequences were downloaded 
and, following translation of the sequences with the tBLASTn algorithm, both 
the antibiotic and AMP resistance proteins were identified using our literature-
curated lists of resistance genes with the same BLAST parameters as before (> 40% 
sequence similarity over at least 80% of the length of the subject protein). Because 
the literature-curated lists of resistance genes contain proteins from various sources 
in addition to the human gut microbiota, only those homologues were considered 
in the set of non-ICE-associated resistance genes that were detected in the genome 
sequences of the HMP database (Supplementary Table 4).
Construction of gut metagenomic libraries. To sample the gut resistome, we 
applied a previously established small-insert shotgun metagenomic protocol11 
with small modifications. This method identifies small genomic fragments that 
decrease drug susceptibility when random genomic fragments are expressed 
from a multicopy plasmid with an inducible promoter. For the construction of 
the metagenomic libraries, human stool samples were obtained from two healthy 
unrelated individuals who had not taken any antibiotics for at least one year before 
sample donation. Throughout the entire study we complied with all relevant 
ethical regulations. The protocol related to human faecal sample collection was 
approved by the Ethical Review Board of the Albert Szent-Györgyi Health Centre, 
University of Szeged (approval ID: 42/2017-SZTE). Written informed consent from 
each participant was obtained before faecal sample collection. Protocols related 
to human faecal sample handling were approved by the Ministry of Agriculture 
(Hungary) (approval ID: TMF/146-9/2017). Gut community DNA was isolated 
immediately after sample donation using the ZR Fecal DNA MiniPrep kit (Zymo 
Research) according to the manufacturer’s instructions (http://www.zymoresearch.
com/downloads/dl/file/id/91/d6010i.pdf). Subsequently, 10 µ g of metagenomic 
DNA from each sample was partially digested with 0.25 U MluCI restriction 
enzyme (New England BioLabs) in 10× CutSmart Buffer (New England BioLabs) at 
37 °C for 20 min, followed by heat inactivation at 85 °C for 20 min. MluCI is a four-
base cutter restriction enzyme that produces overhangs complementary to the ones 
that EcoRI produces. By varying the incubation time or the enzyme concentration, 
the size range of the resulting DNA fragments can be set. The fragmented DNA 
was size selected by electrophoresis on a 1% (mass/volume) agarose gel in 1× 
Tris-acetate-EDTA (TAE) buffer. A gel slice corresponding to 1,500–5,000 bp was 
excised from the gel and DNA was isolated using a GeneJET Gel Extraction and 
DNA Cleanup Micro Kit (Thermo Scientific). pZErO-2 plasmid DNA (5 µ g;  
ThermoFisher) was digested with 25 U EcoRI restriction enzyme (Fermentas) 
in 10× EcoRI Buffer (Fermentas) for 2 h, followed by 20 min heat inactivation 
at 65 °C. After purification with a DNA Clean & Concentrator-5 kit (Zymo 
Research), digested pZErO-2 plasmid was dephosphorylated with FastAP alkaline 
phosphatase (Thermo Scientific) as follows: 4 µ g plasmid DNA was incubated 
with 4 U enzyme in 10× FastDigest buffer at 37 °C for 1 h, followed by 5 min heat 
inactivation at 74 °C and purification with DNA Clean & Concentrator-5 kit (Zymo 
Research). DNA was ligated into pZErO-2 at the EcoRI site using the Rapid DNA 
ligation kit (Thermo Scientific). The ligation reaction was performed in 15 µ l total 
volume using a 5:1 insert–vector ratio: 4.5 µ l (310 ng) digested and gel purified 
DNA insert, 0.65 µ l (62 ng) EcoRI-cut pZErO-2 vector, 3 µ l 5× ligation buffer, 0.75 µ l  
10 mM ATP, 4.1 µ l dH2O, 2 µ l T4 DNA ligase (5 U μ l−1). The ligation mixture was 
incubated at 16 °C overnight, followed by heat inactivation at 65 °C for 10 min.
Before transformation, the ligation mixture was purified with DNA Clean 
& Concentrator-5 kit (Zymo Research). A 3.5 µ l volume of the resulting ligation 
mixture was transformed by electroporation into 50 µ l of electrocompetent E. coli 
DH10B cells (Invitrogen). Electroporation was carried out with a standard protocol 
for a 1 mm electroporation cuvette. Cells were recovered in 1 ml SOC medium, 
followed by 1 h incubation at 37 °C. A 500 µ l volume of the recovered cells was 
plated onto square Petri dishes containing Luria Bertani (LB) agar supplemented 
with 50 µ g ml−1 kanamycin. To assess the library size (number of colony-forming 
units, c.f.u.), 1 µ l of the electroporated cells was saved for plating onto a separate 
Petri dish containing Luria Bertani (LB) agar supplemented with 50 µ g ml−1 
kanamycin. From each plate, 10 clones were randomly picked for colony PCR to 
confirm the presence and the size distribution of the inserts. PCR was performed 
using the Sp6-T7 primer-pair (Supplementary Table 13) flanking the EcoRI site 
of the multiple cloning site of the pZErO-2 vector. The sizes of the PCR products 
were determined by gel electrophoresis and the average insert size was calculated 
to be 2–3 kb. The size of each library was determined by multiplying the average 
insert size by the number of total c.f.u.s. The size distributions of the libraries 
varied between 4.4 and 16 Gb coverage with this protocol, which is in line with a 
previously published state-of-the-art protocol11,18. The resulting colonies from the 
Petri dishes were collected and the plasmid library was isolated using an InnuPREP 
Plasmid Mini Kit (Analytic Jena). Between 30 and 60 ng of isolated plasmid library 
was transformed by electroporation into 40 µ l electrocompetent E. coli BW25113 
(prepared as described in ref. 44). This E. coli strain was used for the functional 
selections (see next section). After electroporation, cells were recovered in 1 ml of 
LB medium for 1 h at 37 °C. Special care was taken to achieve high electroporation 
efficiency to cover 10–100 times the original library size. In this way, we ensured 
that most library members were electroporated from the plasmid library.  
The 1 ml recovered cell culture was added to 9 ml of LB medium supplemented 
with 50 µ g ml−1 kanamycin, and grown at 37 °C for 2–3 h until it reached the 
7.5 × 108 to 10 × 108 cell density (optical density at 600 nm (OD600 of 1.5–2). Cell 
aliquots were frozen in 20% glycerol and kept at − 80 °C for subsequent functional 
selection experiments.
Metagenomic libraries were generated from the uncultured microbiota (the 
total DNA extracted from the stool samples) and also from the cultured microbiota 
(the genomic DNA extracted from the cultured pooled microbiota). For details  
see the section ‘Cultivation of the gut microbiota under anaerobic conditions and 
DNA extraction’.
Functional metagenomic selections for AMP resistance and antibiotic 
resistance genes. Functional selections for resistance were carried out on 
solid plates containing one of the 12 antimicrobial peptides or 11 antibiotics 
(Supplementary Table 5). Instead of the plating assay commonly used in the 
field11, we applied a modified gradient plate assay45 where bacteria are exposed to 
a concentration gradient of the antimicrobial instead of a single concentration. 
We found that this strategy improves the reproducibility of AMP selections, where 
changes in the resistance levels are relatively small compared to that in the case 
of antibiotics. The growth medium in these plates was a modified minimal salt 
medium (MS) with reduced salt concentration (1 g (NH4)2SO4, 3 g KH2PO4,  
7 g K2HPO4, 100 µ l MgSO4 (1 M), 540 µ l FeCl3 (1 mg ml−1), 20 µ l thiamine 
(50 mg ml−1), 20 ml casamino acids (BD) (10% (mass/volume), 5 ml glucose  
(40% (mass/volume)) in a final volume of 1 l), because most AMPs are not effective 
in vitro in the presence of high salt concentrations. In the case of the AMP-
containing plates, the solidifying agent was changed to 1.5% (mass/volume) low 
melting point agarose (UltraPure LMP Agarose, Invitrogen) from 1.5% (mass/
volume) agar to prevent any heat-induced structural damage of the peptides 
during plate pouring. Antibiotics and AMPs were purchased from Sigma and 
ProteoGenix, respectively. Onto each of the gradient plates (Tray plates, SPL Life 
Sciences) 2 × 108 cells were plated out from the thawed stocks of E. coli BW25113 
bearing the metagenomic plasmid libraries. In this way, each metagenomic 
library member was represented about 10–100 times on each plate. We found 
this necessary for good reproducibility of our experiments. Subsequently, plates 
were incubated at 30 °C for 24 h. For each functional selection, a control plate 
was prepared with the same number of E. coli BW25113 plated out. These cells 
contained the pZErO-2 plasmid with a random metagenomic DNA insert that 
has no effect on AMP and antibiotic resistance. This control plate showed the 
minimum inhibitory concentration (MIC) of the antimicrobial without the effect 
of a resistance plasmid. The empty plasmid was not applicable as a control because 
in the absence of a DNA insert the CcdB toxic protein is expressed from the 
plasmid. To isolate the resistant clones from the library plates, sporadic colonies 
were identified above the MIC level (defined using the control plate) by visual 
inspection. These clones were collected by scraping them into 2 ml LB broth and 
then stored at − 80 °C.
Validation of the resistance-conferring metagenomic DNA fragments. Following 
selection of the metagenomic libraries, the putative resistance phenotypes 
conferred by the plasmid selections were confirmed for a representative fraction 
of the colonies. From each selection at least 20 colonies were picked and the 
MIC increase was determined by a standard broth microdilution method46, as 
described in the section ‘Quantification of the resistance gains that metagenomic 
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contigs provide’. For these measurements, the same control plasmid was used 
as in the functional selections. MIC values were determined after 16–24 h of 
incubation at 30 °C with continuous shaking at 240 r.p.m. Plasmids from validated 
resistant clones were re-transformed into the BW25113 E. coli strain, followed 
by a second MIC determination to exclude the possibility that the increase in the 
MIC was induced by genomic mutations. Plasmids not showing a MIC increase 
in the validation protocol were excluded from further analysis. Predominantly, 
clones situated closer than 1 cm to the MIC level on the gradient plates did 
not confer resistance during validation. To avoid these false positive resistance 
plasmids, colonies at the borderline were not collected for further analysis without 
confirming their phenotype. The rest of the colonies were collected by scraping 
them into 2 ml of LB broth. Bacterial samples were stored at − 80 °C in 20% (mass/
volume) glycerol. When only a few clones were on the plates, all were tested for 
resistance to make sure that we did not lose potential hits. We encountered such 
situations only in the case of AMPs. If the number of resistant clones on a plate 
was less than or equal to 20, plasmids were isolated individually from the MIC 
validated clones and sent for Sanger bidirectional sequencing with the Sp6-T7 
primer pair (Supplementary Table 13). When the resistance-conferring insert was 
longer than covered by the initial sequencing, we applied a primer walking strategy 
to sequence the middle part of the insert.
Amplification of the resistance-conferring metagenomic DNA fragments. 
Plasmid pools from the scraped resistant clones were PCR amplified for 
subsequent PacBio sequencing47. To this end, the plasmid pools were first 
isolated from each metagenomic selection using an InnuPREP Plasmid Mini Kit 
(Analytic Jena). Then, these plasmid pools served as templates for subsequent 
PCR amplification reactions to amplify the inserts from the pooled plasmids. 
These PCR reactions were performed with barcoded Sp6 and T7 specific primers 
as forward and reverse primers, respectively. A 16-base PacBio barcode dual-end 
labelling scheme was used to label each plasmid pool for sample identification 
in subsequent PacBio sequencing. The primer sequences are presented in 
Supplementary Table 13. PCR reactions consisted of 30 ng of template DNA, 
Q5 Hot Start High-Fidelity 2× Master Mix (New England BioLabs) and 0.2 μ M 
barcoded primers in a final reaction volume of 25 μ l. Following an optimization 
process, the number of PCR cycles was reduced to 15 to minimize amplification 
bias. The following thermocycler conditions were used: 98 °C for 5 min, 15 cycles of 
98 °C for 15 s + 69 °C for 30 s + 72 °C for 2 min, and 72 °C for 7 min. The amplified 
metagenomic inserts were then cleaned using the DNA Clean & Concentrator-5 kit 
(Zymo Research) and their concentration was measured with a Qubit fluorometer 
(Invitrogen). To get rid of the short amplicons (for example, primer dimers), which 
may interfere with the sequencing process, barcoded amplicons were mixed at an 
equimolar ratio and the sample was gel extracted following electrophoreses using 
1% agarose gel. The sample was purified (Zymoclean Gel DNA Recovery Kit) 
before sequencing.
PacBio sequencing and data analysis. Sequences of the pooled PCR products 
were obtained from the Norwegian Sequencing Centre at the University of Oslo, 
Norway. The library was prepared using the Pacific Biosciences Amplicon library 
preparation protocol. Samples were sequenced with a Pacific Biosciences RS II 
instrument using P6-C4 chemistry and MagBead loading in one SMRT cell. A 
total of 61,641 reads were obtained with a mean length of 20,961 bp. Reads were 
filtered without demultiplexing using the RS_subreads.1 pipeline of the SMRT 
Portal (version 2.3.0) using default settings (no. of passes, 1; minimum accuracy, 
0.9). Following barcode detection and demultiplexing, reads were collapsed to 
consensus sequences using the long amplicon analysis pipeline of the SMRT 
Portal with default settings. We validated our sequencing effort on a mock 
sample containing nine previously sequenced DNA contigs originating from our 
metagenomic selections. Reassuringly, of the nine sequences, eight were present in 
the PacBio sequencing result with at least 99% sequence identity. The single non-
detected contig was the longest (4,500 bp), which may indicate a bias of the pipeline 
towards shorter insert sizes.
Functional annotation and resistance gene identification on the metagenomic 
contigs. To functionally analyse the ORFs on the assembled contigs from the 
metagenomic selections, ORFs were predicted and annotated using the Prokka 
suite (version 1.1148) with bacterial prediction settings and an e-value threshold of 
10−5. Within Prokka, the Prodigal36 sub-script was modified to run without the -c 
parameter to identify highly probable ORFs, even if the ends were not closed. This 
was necessary because some contigs may have been shortened by a few residues 
during the cloning process or in the assembly due to low coverage, without losing 
their functionality. Other parameters were kept as default. Next, ORFs on the 
metagenomic contigs were functionally annotated with our resistance gene lists 
introduced in the section ‘Analysis of the mobile gene pool of the gut microbiota’. 
Specifically, an ORF was classified as an antibiotic resistance gene when a sequence 
similarity search using BLASTP49 against the CARD8 database35 resulted in an 
annotation with an e-value < 10−5, identity > 30% and coverage > 80%. Here, the 
minimum sequence identity was lower than in the case of the analysis of the 
mobile gene pool, because the experimentally observed resistance phenotype 
provided extra confidence for the annotation. Similarly, AMP resistance genes 
were identified by performing a BLASTP sequence similarity search against the 
manually curated list of AMP resistance genes (Supplementary Table 1). We note 
that 55.4% of the antibiotic resistance contigs carried a homologue of a known 
antibiotic resistance gene, and 23.5% of the 34 unique AMP resistant DNA contigs 
encoded a gene that has been associated with AMP resistance in the literature. This 
difference suggests that more AMP resistance genes await discovery. To estimate 
the identity of the donor organisms from which the assembled DNA contig 
sequences originated, a nucleotide sequence similarity search was carried out for 
the entire DNA contigs as query sequences against the genome sequences from the 
HMP database24 using BLASTN, with an e-value threshold of < 10−10. Taxonomy 
was assigned with the ete3 toolkit34.
Cultivation of the gut microbiota under anaerobic conditions and DNA 
extraction. To compare the abundance and phylogenetic distribution of the AMP- 
and antibiotic-resistant gut bacteria, we applied a recently established anaerobic 
cultivation protocol of the human gut microbiota, with small modifications25. For 
this purpose, human faecal samples were obtained from seven healthy unrelated 
volunteers who had not taken any antibiotics for at least one year before sample 
donation. Ethical rules were observed throughout the whole study. Following 
defecation, stool samples were immediately placed into uncapped 50 ml plastic 
tubes (Sarstedt), deposited in anaerobic bags (Oxoid, Thermo Scientific); samples 
were transferred into the anaerobic chamber within 1 h after sample collection. 
All anaerobic experiments were performed in a Bactron IV anaerobic chamber 
(Shel Lab) filled with an atmosphere of 95% nitrogen and 5% hydrogen, with 
palladium catalysts. Two grams of the faecal samples were suspended in 20 ml 
of modified Gifu anaerobic medium (GAM) broth (HyServe). After 10 min of 
incubation, allowing the solid particles to settle down, the supernatants were 
supplemented with 20% glycerol, aliquoted and stored at − 80 °C. Before cultivation 
of the microbiota, thawed aliquots from the samples of the seven individuals were 
combined in an equal ratio (we refer to this sample mix as ‘Faecal 7 mix’ sample) 
in the anaerobic chamber. This Faecal 7 mix sample was plated out anaerobically 
in the presence and absence of one of the five AMPs or one of the five antibiotics 
that were active in the culturing medium (Supplementary Table 5). The culturing 
medium was modified GAM, given that the best reconstruction of the composition 
and architecture of the human gut bacterial community could be obtained using 
this medium25. In the case of AMP-containing plates, the solidifying agent was 
low melting agarose instead of agar for the same reason as before (see section 
‘Functional metagenomic selections for AMP and antibiotic resistance genes’). 
Each AMP and antibiotic was applied in three different concentrations on separate 
plates with three replicates.
To mimic the thermal conditions encountered by the gut bacteria in the human 
intestinal tract, plates were incubated at 37 °C in the anaerobic chamber for 4 days. 
After a 4 day time interval, we observed a plateau in the number of colonies appearing. 
Following colony counts the plates had to fulfil two requirements to be selected for 
subsequent analysis. First, colony numbers needed to be in the range of 0.01–0.1% as 
compared to the colony numbers in the absence of any AMP and antibiotic treatment 
(we refer to these samples as ‘untreated’). Second, colony numbers needed to be 
high, but still in the countable range (1,000–5,000 colonies). To be in this range, 
the untreated Faecal 7 mix sample was plated out in a concentration 1,000-fold 
more dilute than used for the AMP and antibiotic selections. For Trimethoprim 
the selection pressure could not be increased enough to select for the most resistant 
0.01–0.1% of the population because 0.49% of the colonies were able to grow even at 
the solubility limit of this antibiotic. From the selected plates, resistant colonies were 
scraped and the pooled colonies from each plate were used to isolate genomic DNA 
with a ZR Fecal DNA MiniPrep kit (Zymo Research) according to the manufacturer’s 
instructions. The isolated DNA samples were subsequently used for both small-insert 
shotgun library constructions (referred to as libraries from cultured microbiota, 
Supplementary Table 10) and for 16S rRNA-based community profiling. To estimate 
the relative resistance level of the gut microbiota compared to E. coli BW25113, we 
used the colony counts from the anaerobic cultivation experiments at each AMP and 
antibiotic concentration; that is, the resistance level of the gut microbiota against an 
AMP and antibiotic is defined as the AMP and antibiotic concentration at which only 
0.1–0.01% of the untreated microbiota population could grow, analogous to an MIC 
value determination for a single species. The susceptibility of E. coli was estimated 
in the same way as for the gut microbiota by plating out anaerobically the same 
number of cells as in the case of the Faecal 7 mix sample for each AMP and antibiotic 
treatment. Then we determined the AMP and antibiotic concentrations at which 
only 0.1–0.01% of the E. coli cells could grow. The relative resistance level of the gut 
microbiota was defined as the resistance level of the gut microbiota divided by the 
resistance level of E. coli (Supplementary Table 8).
16S rRNA-based bacterial community profiling. To determine the taxonomic 
composition of the AMP- and antibiotic-resistant gut bacterial communities, we 
sequenced and analysed the V4 region of the 16S rRNA genes from the Faecal 
7 mix samples cultivated in the presence of individual AMPs and antibiotics. 
We also determined the phylogenetic composition of the uncultivated Faecal 
7 mix sample. The V4 region of the 16S rRNA gene was PCR amplified with 
dual-indexed Illumina primer pairs, using different combinations of barcoded 
forward and reverse primers (v4.SA501-505 and v4.SA701-706, respectively, 
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Supplementary Table 13) as previously described50. The primers consist of the 
appropriate Illumina adapters, an 8 nt index sequence, a 10 nt pad sequence, a 2 nt 
linker and specific sites for the V4 region. The PCR reactions consisted of 1.5 μ l 
(30 ng) of template DNA, 10 μ l of Phusion HF buffer (Thermo Fisher Scientific), 
4 μ l of 2.5 mM deoxynucleotide triphosphates mix (dNTPs), 0.5 μ l of Phusion DNA 
polymerase (2 U µ l−1) (Thermo Fisher Scientific), 1–1 μ l of primers, 10 μ M each, 
3 μ l DMSO (100%) and 29 μ l of nuclease-free H2O in a final reaction volume of 
50 μ l. The following thermocycler conditions were used: 95 °C for 2 min, 25 cycles 
of 95 °C for 20 s + 56 °C for 15 s + 72 °C for 5 min and 72 °C for 10 min. Following 
gel electrophoreses of the PCR products, the 400 bp amplicons were extracted 
from the gel (Thermo Scientific GeneJET Gel Extraction Kit) and, following a 
second purification step (Zymo Research DNA Clean & Concentrator-5 Kit), 
were sequenced using the MiSeq Illumina platform. To prepare the samples for 
sequencing, the amplicons were quantified using a fluorometric method (Qubit 
dsDNA BR Assay Kit, Thermo Fischer Scientific) and libraries were mixed 
with Illumina PhiX in a ratio of 0.95:0.05. Sequencing on the Illumina MiSeq 
instrument was carried out with a v2 500 cycle sequencing kit (Illumina). 100 µ M 
stock custom sequencing primers49 were mixed with standard read1, index read 
and read2 sequencing primers included in the MiSeq cartridge.
After sequencing, 16S rRNA reads were demultiplexed and processed with the 
Mothur software (version 1.36.151). There were 21,979 average counts per sample. 
To filter out the low read counts we followed the protocol of ref. 25. The number 
of sequences per sample was equalized to 20,000 read counts using random 
re-sampling with a custom R script. Reassuringly, 20,000 read counts is well above 
the threshold where phylogenetic diversities show saturation in the samples (see 
the rarefaction curves of samples in Supplementary Fig. 12, which were calculated 
using the vegan (version 2.4–352) R package). Sequences were merged at the level of 
97% sequence identity and taxonomically assigned using the Silva ribosomal RNA 
database38. OTUs were classified at the family level because the V4 region allows 
accurate identification only down to this level53 (Supplementary Table 7). After 
removal of reads that could not be classified, 362 OTUs remained. To evaluate the 
reproducibility of the cultivation and sequencing, we generated seven replicates 
from the untreated samples. Samples referred to as ‘Untreated 1–5’ originate from 
independent cultivation experiments started from different aliquots of the same 
five frozen samples (Supplementary Figs. 7 and 12). In the case of ‘Untreated 5, 5i 
and 5ii’ samples, cultivations were started from the same sample and cultures were 
grown in parallel (Supplementary Figs. 7 and 12).
To quantify within-sample diversity from 16S rRNA data, we used the vegan R 
package to calculate the most commonly used alpha diversity indices54,55 (Shannon 
index, Fig. 3a; Fisher’s and inverse Simpson indices, Supplementary Fig. 8). 
Unweighted Unifrac distances (Fig. 3b) were computed with Phyloseq (version 
1.22.3 R package56).
To identify differentially abundant bacterial families in the resistance 
microbiota, we applied edgeR (version 3.16.5 R package57) on the family-level 
16S rRNA abundance data of the cultured microbiota samples, as suggested 
previously58. To this end, abundances were normalized using the TMM (trimmed 
mean of M-values) method59 and then untreated and AMP- and antibiotic-treated 
samples were compared using negative binomial tests in a pairwise manner. We 
used the Benjamini–Hochberg false discover rate correction method to correct the 
P values for multiple testing60.
Comparing the prevalence of AMP and antibiotic resistance genes in gut 
microbial genomes. To assess if the large taxonomic diversity in the AMP-resistant 
microbiota corresponds to a diverse reservoir of AMP resistance genes, we 
compared the prevalence of previously described AMP and antibiotic resistance 
gene families in a representative set of gut microbial genomes as follows. Genome 
sequences used for the analysis of the mobile gene pool (Supplementary Table 2) 
were filtered to retain only those sequences that belong to one of the AMP- and 
antibiotic-resistant bacterial families (Supplementary Table 7). In this analysis, we 
used only the genome sequences from the Human Microbiome Project, because 
the family-level taxonomic assignments of the genome sequences were sporadic 
in the Fijicomp cohort. In the remaining data set 24 AMP- and 26 antibiotic-
resistant bacterial families were represented with 222 and 219 genome sequences, 
respectively. To avoid sampling bias due to the unequal representation of species 
among the genome sequences, one genome sequence was randomly picked from 
each genome group (genomes with lower than 2% 16S rRNA gene dissimilarities; 
for details see section ‘Analysis of the mobile gene pool of the gut microbiota’). 
Then, for each known AMP and antibiotic resistance gene family, the genomes with 
at least one positive annotation were counted and plotted (Supplementary Fig. 9).
Comparing phylum-level distributions of the resistant microbiota and the 
transferring resistance contigs. To compare the phylum-level distributions of 
resistant gut bacteria and the resistance contigs originating from them (Fig. 3d), 
we carried out logistic regression analyses on count data (Supplementary Table 
11) as follows. For each phylum, we fitted a logistic regression model to predict 
if a resistant gut microbiota colony or resistance-conferring contig belonged to 
that particular phylum or to the other phyla. Thus, each entry in the data set 
represented either a colony from the drug-treated cultivation experiment or a 
resistance contig detected in the functional metagenomics screen. The predictor 
variables of the models were (1) whether the entry was a resistance contig or 
a cultivated colony, (2) the type of treatment (AMP or antibiotic) and (3) the 
interaction of these two variables. As we were interested in whether a given phylum 
contributed disproportionally more (or less) AMP than antibiotic resistance 
contigs compared to its relative frequency in the drug-treated cultured microbiota, 
we tested if the interaction term of the logistic regression model was significant 
(using the glm function of R).
Comparison of resistance levels in E. coli and S. enterica. To investigate whether 
the level of resistance provided by AMP resistance genes depends more on the 
genetic background of the recipient bacterium than in the case of antibiotic 
resistance genes, we measured how DNA fragments that provide AMP or antibiotic 
resistance to E. coli influence susceptibility in a related Enterobacter species,  
S. enterica serovar Typhimurium LT2. For this purpose, we used a representative 
set of plasmids carrying resistance DNA fragments that were isolated in our screens 
from AMP and antibiotic treatments (Supplementary Table 12). Special care was 
taken to avoid the inclusion of multiple plasmids carrying resistance genes with the 
same function or bias toward certain AMPs and antibiotics. To this end, from each 
AMP and antibiotic selection we chose 1–5 plasmids carrying resistance genes with 
different functions. This resulted in 16 plasmids and 25 AMPs and antibiotics. The 
provided resistance levels (MIC fold changes) were measured for both species with 
standard micro-dilution assays, in the same way as in the next section.
Quantification of the resistance gains that metagenomic contigs provide. To 
investigate the resistance gains that contigs provide for the recipient bacteria 
against AMP and antibiotic treatments, we carried out MIC measurements with 
selected contigs from the uncultured and cultured microbiota. The resistance gains 
were quantified by measuring MIC values with a standard broth microdilution 
method61. Briefly, 5,000 E. coli and S. enterica cells grown overnight in MS medium 
with 50 µ g ml−1 kanamycin were used to inoculate the wells of a 96-well plate. Three 
rows on the plate were inoculated with the strain in question and three rows with 
control cells. As a control, E. coli BW25113 or S. enterica serovar Typhimurium LT2 
strains carrying the control plasmid were used as in the functional metagenomic 
selection experiments. Before inoculation, each well on the plate was pre-filled 
with 100 µ l modified MS medium supplemented with the proper concentration of 
AMP or antibiotic. On the plate, each AMP and antibiotic was represented in 11 
different concentrations (three wells per concentration per clone or control). Three 
wells per genotype contained only medium to check the growth in the absence 
of any antimicrobial. MIC values were determined by measuring OD600 after 
16–24 h of incubation at 30 °C with continuous shaking at 240 r.p.m. To minimize 
potential evaporation of the medium and consequent plate edge effects, 96-well 
plates were incubated at 30 °C following standard laboratory procedures for MIC 
measurements.
Functional analysis of a putative LpxF from the metagenomic selections. The 
aim of the functional characterization was twofold: (1) to support the functional 
prediction for the identified LpxF orthologues with a biochemical assay; (2) 
to estimate quantitatively the extent to which these LpxF orthologues reduce 
the net negative surface charge of the bacterial cell as compared to a previously 
characterized LpxF from F. novicida that removes > 90% of the 4′ -phosphate groups 
from the penta-acylated lipid A molecules and hence alters the charge of the outer 
membrane62. To estimate the surface charge of bacterial cells, we used a fluorescein 
isothiocyanate (FITC)-labelled poly-l-lysine (PLL) (FITC–PLL; Sigma-Aldrich) 
based assay. PLL is a polycationic molecule, widely applied to study the interaction 
between charged bilayer membranes and cationic peptides63. The following strains 
were used in this measurement: E. coli BW25113 (WT), E. coli BW25113 carrying 
the pZErO-2 plasmid with the LpxF orthologue from P. merdae (denoted lpxFa  
in Table 1), identified in our functional selection experiments (WT + lpxF), E. coli 
BW25113 Δ lpxM (Δ lpxM), E. coli BW25113 Δ lpxM carrying the pZErO-2  
plasmid with the LpxF orthologue from P. merdae (Δ lpxM + lpxF), E. coli 
BW25113 Δ lpxM carrying the pWSK29 plasmid with LpxF from F. novicida62 
(Δ lpxM + lpxF*) and B. thetaiotaomicron. We measured the phenotypic effect 
of both LpxF carrying plasmids on Δ lpxM genetic background, because LpxF 
from F. novicida cannot carry out its biological function in wild-type E. coli, only 
when the lipid A molecules are tetra- or penta-acylated as in the case of Δ lpxM 
E. coli62. B. thetaiotaomicron intrinsically expresses the BT1854 lpxF orthologue 
(lpxF**), which is responsible for the high level of resistance of this strain against 
polymyxin B12. Before the surface charge measurements, cells were grown 
overnight in tryptone yeast extract glucose (TYG) medium64 under anaerobic 
conditions. We grew all the strains in TYG medium to allow comparability with 
B. thetaiotaomicron. Cells were washed twice with phosphate-buffered saline 
(PBS) then resuspended to a cell density of OD600 = 1. Cells were incubated with 
2 µ l of 5 mg ml−1 FITC–PLL and 100 µ l of 1 µ g ml−1 4,6-diamidino-2-phenylindole 
(DAPI) for 10 min, followed by centrifugation (4,500 r.p.m., 5 min). DAPI was used 
to identify the live cells. Cells were washed twice with PBS then diluted 100-fold 
in 100 µ l of PBS and transferred into a black clear-bottomed 96-well microplate 
(Greiner Bio-One). Before fluorescent microscopy analysis, cells were collected 
to the bottom of the plate by centrifugation (4,500 rpm, 10 min). Pictures were 
taken with a PerkinElmer Operetta microscope using a × 60 high-NA objective to 
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visualize the cells. Images of two channels (DAPI and FITC–PLL) were collected 
from ten sites for each well. Mean fluorescent intensity for each well was calculated 
using Harmony High Content Imaging and Analysis Software. Experiments were 
carried out in four biological replicates.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The GenBank accession nos. for the PacBio sequencing data are MH883365–
MH883616. 16S rRNA sequencing reads are available from the Sequence Read 
Archive (SRA) (BioProject PRJNA494380). All data generated or analysed during 
this study are included in this article and its Supplementary Information. For 
each figure, the availability of the analysed data is indicated in the legend. All 
accession numbers with information on the associated samples are provided as 
Supplementary Data.
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